← All trials
NCT07026968
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 20, 2025
- Primary completion
- Oct 30, 2026
- Completion date
- Nov 13, 2026
- First posted
- Jun 18, 2025
- Last posted
- Sep 29, 2025
- Enrollment
- 815
- Arms / groups
- 5 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Yiling Pharmaceutical Inc.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.